|
|
Experience summary of Professor Lao Changhui in treating lung adenocarcinoma by using the “cold-dampness due to kidney deficiency” theory |
XU Feilong ZENG Qigang LAO Changhui WEI Chenggong |
Department of Respiratory, Guangdong Traditional Chinese and Western Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine, Guangdong Province, Foshan 528200, China |
|
|
Abstract Lung adenocarcinoma is one of the most common malignant lung tumors. Its high recurrence rate and low survival rate are becoming more and more serious. Conventional methods, such as conventional surgery, radiochemotherapy and molecular targeted therapy, still have great limitations. Through years of clinical observation and practice, Professor Lao Changhui concludes that the key pathogenesis of occurrence and metastasis of lung adenocarcinoma is “cold-dampness due to kidney deficiency”, and around this pathogenesis, he puts forward the basic treatment of “cultivating yuan, tonifying kidney, dispelling yin and cold” throughout the treatment process. With the intervention of course of disease and treatment, cancerous accumulation may turn toxic and heat, leading to the changes of pathogenesis of deficiency of both qi and yin and deficiency of both yin and yang. Therefore, “cultivating yuan, tonifying kidney, dispelling yin and cold” should be used throughout the treatment process. At the same time, according to the changes of course of disease and syndrome, it should be added and subtracted with syndrome. On the premise of taking care of healthy qi, it can be supplemented with less specialized anti-cancer drugs. This reflects the advantages of traditional Chinese medicine thinking of “people oriented, syndrome differentiation and treatment”.
|
|
|
|
|
[1] Tan LM,Qiu CF,Zhu T,et al. Genetic polymorphisms and platinum-based chemotherapy treatment outcomes in patients with non-small cell lung cancer:a genetic pidemiology study based meta-analysis [J]. Sci Rep,2017,7(1):5593.
[2] Herbst RS,Morgensztern D. The biology and management of non-small cell lung cancer [J]. Nature,2018,553(7689):446-454.
[3] 郑佳彬,袁嘉萌,刘益华,等.中医药联合化疗治疗晚期非小细胞肺癌临床疗效的研究进展[J].中华中医药杂志,2018,33(11):5026-5030.
[4] 方乃青,肖寒.肺癌辨证论治特点探析[J].江苏中医药,2011,43(12):5-7.
[5] 于洁,王祥麒,王俊涛,等.王祥麒教授基于“肾主骨”理论妙治乳腺癌骨转移[J].中医临床研究,2018,10(26):106-107.
[6] 朴永吉,齐华平,唐蕙,等.癌因性疲乏临床研究中传统中药的研究现状[J].中国临床药理学杂志,2019,35(13):1395-1397.
[7] 曾崎冈,戴勇,老昌辉,等.补肾培元胶囊对非小细胞肺癌患者化疗后免疫功能的影响[J].临床合理用药杂志,2020,13(1):60-61.
[8] 戴勇,曾崎冈,老昌辉,等.补肾培元胶囊对慢性阻塞性肺疾病肾阳虚证炎症因子及热休克蛋白水平的影响[J].中国医药导报,2018,15(24):133-136.
[9] 戴勇,曾崎冈,魏成功,等.补肾培元胶囊调控MKP-1/JNK抑制A549细胞增殖及诱导细胞凋亡实验研究[J].山西中医,2018,34(12):42-46.
[10] 周艳丽,许剑怡,王宏娟,等.虫草素的药理作用及应用前景[J].中国医药导报,2020,17(8):39-42.
[11] 邱涵,吕晓君,张鹏.冬虫夏草西洋参复合物增强免疫力功能实验研究[J].中国医药导报,2016,13(9):18-22.
[12] 刘智勤,陈鹊汀,李岩,等.肉苁蓉对化疗荷瘤小鼠增效减毒作用的研究[J].时珍国医国药,2011,22(4):1037-1038.
[13] 司高.核桃仁醇提物抑制癌细胞生长相关蛋白表达的作用[J].中医研究,2011,24(2):9-10.
[14] 叶春林,KHUDOYBERDIEV Ilkhomjon,陈颖,等.菟丝子多糖的抗氧化活性和抑制肿瘤细胞增殖的研究[J].河南工业大学学报:自然科学版,2020,41(5):73-78.
[15] 冯阳,施京红.从化疗的不良反应探讨“培土生金”法在肺癌中的应用[J].世界最新医学信息文摘,2019,19(26):218.
[16] 刘静,朱琦.健脾中药减少大肠癌患者化疗不良反应的系统评价[J].中国循证医学杂志,2009,9(7):802-808.
[17] 谢璐帆,蔡艳阳,张恺,等.扶正祛邪中药联合化疗对中晚期胰腺癌患者临床疗效影响的Meta分析[J].中华中医药杂志,2017,32(8):3703-3707.
[18] 陈雨,林青,刘传波,等.癌性疼痛的中医治疗进展[J].医学综述,2020,26(20):4112-4116.
[19] 李霞,门九章.门纯德兴阳法在失眠重症中的应用[J].山西中医,2012,28(8):9-10.
[20] 王振强,高秀敏,黄如敬,等.中药内服方治疗癌性疼痛临床用药频次分析[J].中国中医药现代远程教育,2019, 17(3):51-53.
[21] 鲍舒洁,张丹,张红,等.白芍总苷脂质体诱导胃癌BGC-823细胞凋亡的实验研究[J].中国药学杂志,2016,51(24):2109-2113.
[22] 代倩倩,夏欢,夏桂阳,等.白芍方药以及白芍总苷镇痛功效及其机理研究进展[J].世界科学技术-中医药现代化,2020,22(1):39-46.
[23] 蔡云,陈远彬,叶放,等.国医大师周仲瑛从癌毒理论辨治肺癌经验述要[J].中华中医药杂志,2020,35(6):2879-2882.
[24] 黄海福.以毒攻毒法治疗肿瘤的认识与思考[J].现代诊断与治疗,2015,26(23):5495-5496.
[25] 瞿美霞,徐金中.抗肿瘤药物的不良反应分析与防治[J].医药导报,2010,29(3):394-396. |
|
|
|